Pediatrix Medical Group (MD) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was $511.2 million, up 0.9% year-over-year, driven by higher same-unit revenue and favorable payer mix, with same-unit revenue up 5.2% and patient volumes stable to positive across core service lines.

• Net income for Q3 2024 was $19.4 million, down from $21.4 million in Q3 2023; Adjusted EBITDA rose to $60.2 million from $50.4 million, and Adjusted EPS increased to $0.44 from $0.32.

• The transition to a hybrid revenue-cycle management structure was completed without operational disruption, and portfolio restructuring, including exits from office-based and primary/urgent care practices, is on track to finish by year-end.

• For the nine months ended September 30, 2024, net revenue was $1.51 billion, with a net loss of $129.5 million due to $154.2 million in goodwill impairment and $38.4 million in asset impairments.

• Leadership transition in the CFO role was highlighted, with a focus on data-driven decision-making and operational efficiency.

Financial highlights

• Q3 2024 net revenue: $511.2 million (+0.9% year-over-year); nine months: $1.51 billion (+0.8%).

• Q3 2024 net income: $19.4 million; nine months: net loss of $129.5 million (vs. net income of $63.9 million in 2023).

• Q3 2024 Adjusted EBITDA: $60.2 million (vs. $50.4 million in 2023); nine months: $155.3 million (vs. $149.6 million in 2023).

• Q3 2024 diluted EPS: $0.23 (vs. $0.26 in 2023); nine months: $(1.56) (vs. $0.77 in 2023).

• Operating margin for Q3 2024 was 6.6% (10.3% excluding restructuring); nine months: (7.1)% (8.3% excluding impairments and restructuring).

Outlook and guidance

• 2024 Adjusted EBITDA guidance narrowed to $205–$215 million, reflecting progress on operating plans and restructuring.

• Portfolio management exits are expected to be completed by year-end, with an estimated $30 million annualized benefit to Adjusted EBITDA, one-third realized in 2024 and the remainder in 2025 and beyond.

• G&A expense for 2024 is expected to be comparable to 2023 on a dollar basis.

• Sufficient liquidity is anticipated for at least the next 12 months, supported by $103.8 million in cash and $450 million in available credit.